The MARIPOSA study (NCT04487080) compares the efficacy and safety of amivantamab–lazertinib combination therapy versus single-agent osimertinib and the AMIGO-1 trial evaluates the combination of amivantamab–lazertinib with platinum-pemetrexed based chemotherapy in treatment naïve EGFR-mutated NSCLC (NCT05299125). This evidence concerns the gene EGFR and non-small cell lung carcinoma.